TRANSGENE S.A. · Strasbourg France (Euronext Paris: TNG)
| 11 Rue De Molsheim | Phone: +33-3-88-27-91-00 |
| Strasbourg | Fax: +33-3-88-22-58-07 |
| 67082 | |
| France | 
Map This Company |
TRANSGENE S.A. Rankings
Company Description
TRANSGENE's expertise in gene therapy may help it transform into a cancer fighter. The biotech company is focusing its research and development efforts on its two most promising cancer vaccine candidates. One uses two antigens from the human papillomavirus (HPV) to treat cervical cancer, while the other candidate targets breast, lung, prostate, lung, and other cancers. In addition to these two projects, TRANSGENE is developing two immune therapy adjuvants that are injected directly into tumors in addition to other cancer therapy products. Contract research and licensing revenues account for all of the company's profit. Chairman Christophe Mérieux and his family control 70% of TRANSGENE.
TRANSGENE S.A. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - Euronext Paris: TNG Headquarters |
|---|---|
| Fiscal Year-End | December |
| Employees | 266 |
Executives
14 executives listed for TRANSGENE S.A.'s Strasbourg, France location.
| Chairman | Michel Dubois | |
|---|---|---|
| CEO and Director | Philippe Archinard | |
| VP and CFO | Philippe Poncet |